SANTA ROSA, CA – December 5, 2010 – Osseon Therapeutics, Inc. today named Mr. Gary Coughlen, CPA as the company’s Chief Financial Officer, effective immediately.
Mr. Coughlen was most recently the Chief Financial Officer, of PolyRemedy, Inc., a private-equity medical device company focused on wound care management. Prior to PolyRemedy, he served as the CFO of Refractec Inc., a manufacturer, and distributor of ophthalmic surgical devices to the global market. Coughlen started in 1999 at the founder’s stage with three employees and served as Refractec’s CFO through its growth to 75 employees.
Earlier in his career, Coughlen served as CFO at Scieran Technologies, Inc and was a Vice President at Sierra Capital. He began his career in the public accounting at PricewaterhouseCoopers.
“I’m looking forward to the opportunities ahead for Osseon,” said Coughlen. “We have an incredible pipeline of products, a solid distribution plan and we are well-positioned for growth.”
“Gary brings outstanding expertise to Osseon,” said John Stalcup, Ph.D., CEO and President. “He has a broad range of experience in senior financial management positions with medical device companies, and an extensive background in the equity and debt capital markets. We welcome him to our leadership team and look forward to his contributions to Osseon.”
Coughlen is a graduate of University of Washington, where he earned a bachelor’s degree in Business Administration and UC-Berkley where he completed his Masters in Business Administration.
Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the lower portion of the thoracic and the entire lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union. For more information, visit our web site at www.osseon.com.
Osseon is a registered trademark of Osseon Therapeutics, Inc.
The names of actual companies and products mentioned herein may be the trademarks of their respective owners.
CONTACT: Michael Bivens, Director of Business Development, Osseon Therapeutics, 707.636.5953